Allogeneic stem cell transplantation benefits for patients 60

Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT 3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation by Xavier Poiré, Myriam Labopin, Emmanuelle Polge, Jakob Passweg, Charles Craddock, Didier Blaise, Jan J. Cornelissen, Liisa Volin, Nigel H. Russell, Gérard Socié, Mauricette Michallet, Nathalie Fegueux, Patrice Chevallier, Arne Brecht, Mathilde Hunault-Berger, Mohamad Mohty, Jordi Esteve, and Arnon Nagler haematol Volume 103(2): 256 -265 January 31, 2018 © 2018 by Ferrata Storti Foundation

Patient characteristics of the entire cohort. Xavier Poiré et al. Haematologica 2018; 103: 256

CR 1 patients’ characteristics. Xavier Poiré et al. Haematologica 2018; 103: 256 -265 ©

Cumulative incidence of chronic graft-versus-host disease (Gv. HD). Xavier Poiré et al. Haematologica 2018;

Multivariate analysis using a Cox proportional hazards model, N=291. Xavier Poiré et al. Haematologica

Non-relapse mortality (NRM), relapse incidence (RI), overall survival (OS) and leukemia-free survival (LFS) per disease status (first complete remission (CR 1), second remission (CR 2) and active disease (Active D)). Xavier Poiré et al. Haematologica 2018; 103: 256 -265 © 2018 by Ferrata Storti Foundation

Multivariate analysis using a Cox proportional hazards model, N=212 (CR 1 patients). Xavier Poiré

Graft-versus-host disease and relapse-free survival (GRFS) per disease status (first complete remission (CR 1), second remission (CR 2) and active disease (Active D)). Xavier Poiré et al. Haematologica 2018; 103: 256 -265 © 2018 by Ferrata Storti Foundation